Prognostic impact of electrocardiographic signs in patients with Type2 diabetes and cardiovascular disease: Results from the PROactive study

Diabetic Medicine

Volumn 28, Issue 10, 2011, Pages 1206-1212

  Pfister, R ^a   Cairns, R ^b   Erdmann, E ^a   Schneider, C A ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Isaac Newton Centre   (United Kingdom)

Author keywords

Atrial fibrillation; Bundle branch block; Diabetes; Heart rate; QT interval

Indexed keywords

PIOGLITAZONE; PLACEBO;

ACUTE CORONARY SYNDROME; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EVALUATION; COMORBIDITY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DISEASE DURATION; ELECTROCARDIOGRAPHY; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT AXIS DEVIATION; HEART LEFT BUNDLE BRANCH BLOCK; HEART RATE; HEART RIGHT BUNDLE BRANCH BLOCK; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREDICTIVE VALUE; PROGNOSIS; QT INTERVAL; RISK ASSESSMENT; STROKE;

ADULT; ATRIAL FIBRILLATION; BUNDLE-BRANCH BLOCK; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 80052982315     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2011.03281.x     Document Type: Article

References (29)

1. Stern S, Sclarowsky S. The ECG in diabetes mellitus. Circulation 2009; 120: 1633-1636.
2. Chugh SS, Reinier K, Singh T, Uy-Evanado A, Socoteanu C, Peters D et al. Determinants of prolonged QT interval and their contribution to sudden death risk in coronary artery disease: the Oregon Sudden Unexpected Death Study. Circulation 2009; 119: 663-670.
3. Nichols GA, Reinier K, Chugh SS. Independent contribution of diabetes to increased prevalence and incidence of atrial fibrillation. Diabetes Care 2009; 32: 1851-1856.
4. Guzman E, Singh N, Khan IA, Niarchos AP, Verghese C, Saponieri C et al. Left bundle branch block in type2 diabetes mellitus: a sign of advanced cardiovascular involvement. Ann Noninvasive Electrocardiol 2004; 9: 362-365.
5. Ewing DJ, Boland O, Neilson JM, Cho CG, Clarke BF. Autonomic neuropathy, QT interval lengthening, and unexpected deaths in male diabetic patients. Diabetologia 1991; 34: 182-185.
6. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003; 26: 1553-1579.
7. Stettler C, Bearth A, Allemann S, Zwahlen M, Zanchin L, Deplazes M et al. QTc interval and resting heart rate as long-term predictors of mortality in type1 and type2 diabetes mellitus: a 23-year follow-up. Diabetologia 2007; 50: 186-194.
8. Cardoso CR, Salles GF, Deccache W. Prognostic value of QT interval parameters in type2 diabetes mellitus: results of a long-term follow-up prospective study. J Diabetes Complications 2003; 17: 169-178.
9. Linnemann B, Janka HU. Prolonged QTc interval and elevated heart rate identify the type2 diabetic patient at high risk for cardiovascular death. The Bremen Diabetes Study. Exp Clin Endocrinol Diabetes 2003; 111: 215-222.
10. Okin PM, Devereux RB, Lee ET, Galloway JM, Howard BV. Electrocardiographic repolarization complexity and abnormality predict all-cause and cardiovascular mortality in diabetes: the Strong Heart Study. Diabetes 2004; 53: 434-440.
11. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004; 27: 1647-1653.
12. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK et al. Secondary prevention of macrovascular events in patients with type2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
13. Rautaharju PM, Surawicz B, Gettes LS, Bailey JJ, Childers R, Deal BJ et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. Circulation 2009; 119: e241-e250.
14. Surawicz B, Childers R, Deal BJ, Gettes LS, Bailey JJ, Gorgels A et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol 2009; 53: 976-981.
15. Sagie A, Larson MG, Goldberg RJ, Bengtson JR, Levy D. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol 1992; 70: 797-801.
16. Du X, Ninomiya T, de GB, Abadir E, Chalmers J, Pillai A et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J 2009; 30: 1128-1135.
17. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D'Agostino RB Sr et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 2009; 373: 739-745.
18. Butler J, Kalogeropoulos A, Georgiopoulou V, Belue R, Rodondi N, Garcia M et al. Incident heart failure prediction in the elderly: the health ABC heart failure score. Circ Heart Fail 2008; 1: 125-133.
19. Kannel WB, D'Agostino RB, Silbershatz H, Belanger AJ, Wilson PW, Levy D. Profile for estimating risk of heart failure. Arch Intern Med 1999; 159: 1197-1204.
20. Palatini P, Benetos A, Grassi G, Julius S, Kjeldsen SE, Mancia G et al. Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens 2006; 24: 603-610.
21. Giannoglou GD, Chatzizisis YS, Zamboulis C, Parcharidis GE, Mikhailidis DP, Louridas GE. Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol 2008; 126: 302-312.
22. Sumner G, Salehian O, Yi Q, Healey J, Mathew J, Al-Merri K et al. The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial. J Cardiovasc Electrophysiol 2009; 20: 781-787.
23. Jeong JH, Kim JH, Park YH, Han DC, Hwang KW, Lee DW et al. Incidence of and risk factors for bundle branch block in adults older than 40years. Korean J Intern Med 2004; 19: 171-178.
24. Festa A, D'Agostino R Jr, Rautaharju P, Mykkanen L, Haffner SM. Relation of systemic blood pressure, left ventricular mass, insulin sensitivity, and coronary artery disease to QT interval duration in nondiabetic and type2 diabetic subjects. Am J Cardiol 2000; 86: 1117-1122.
25. Boccalandro F, Velasco A, Thomas C, Richards B, Radovancevic B. Relations among heart failure severity, left ventricular loading conditions, and repolarization length in advanced heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2003; 92: 544-547.
26. Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J et al. Pioglitazone use and heart failure in patients with type2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007; 30: 2773-2778.
27. Boner G, Cooper ME, McCarroll K, Brenner BM, de ZD, Kowey PR et al. Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. Diabetologia 2005; 48: 1980-1987.
28. Tikkanen JT, Anttonen O, Junttila MJ, Aro AL, Kerola T, Rissanen HA et al. Long-term outcome associated with early repolarization on electrocardiography. N Engl J Med 2009; 361: 2529-2537.
29. Kannel WB, Wilson P, Blair SN. Epidemiological assessment of the role of physical activity and fitness in development of cardiovascular disease. Am Heart J 1985; 109: 876-885.